SNSE - Utang jangka cendhak marang modal Sensei Bio

Sensei Biotherapeutics (SNSE) develops antibodies to combat tumors, planning to expand its oncology presence through B2B deals. Meanwhile, the company delegates all clinical trials to external contractors, achieving high operational efficiency. This price chart, which assists in the basic asset valuation, demonstrates the 0.08 indicator. Business development relies on close collaboration with leading scientific centers and clinics to implement innovations.

This ratio measures the proportion of liabilities maturing within one year relative to equity, reflecting the intensity of short-term debt financing used to maintain liquidity. For Sensei Biotherapeutics (SNSE), whose expenses are limited to laboratory standards and reagent safety, the history of short-term loans to equity serves as an indicator of operational flexibility in financing clinical trials.